Mixed fibrinolytic phenotypes in decompensated cirrhosis and ACLF with hypofibrinolysis in those with complications and poor survival

Hepatology

Short-term hemodynamic effects of β-blockers influence survival of patients with decompensated cirrhosis

J Hepatol.

Tapias EA, Ardevol A, Garcia-Guix M, Montañés R, Pavel O, Cuyas B, Graupera I, Brujats A, Vilades D, Colomo A, Poca M, Torras X, Guarner C, Concepción M, Aracil C, Torres F, Villanueva C

doi: 10.1016/j.jhep.2020.03.048.

Hepatology

Vitamin E Improves Transplant-free Survival and Hepatic Decompensation among Patients with NASH and Advanced Fibrosis

doi: 10.1002/hep.30368.

Hepatology

Targeted lipidomics reveals extensive changes in circulating lipid mediators in patients with acutely decompensated cirrhosis

J Hepatol.

López-Vicario C, Checa A, Urdangarin A, Aguilar F, Alcaraz-Quiles J, Caraceni P, Amorós A, Pavesi M, Gómez-Cabrero D, Trebicka J, Oettl K, Moreau R, Planell N, Arroyo V, Wheelock CE, Clària J

doi: 10.1016/j.jhep.2020.03.046.

Hepatology

PREDICT identifies precipitating events associated with the clinical course of acutely decompensated cirrhosis

J Hepatol

Trebicka J, Fernandez J, Papp M, Caraceni P, Laleman W, Gambino C, Giovo I, Uschner FE, Jansen C, Jimenez C, Mookerjee R, Gustot T, Albillos A, Bañares R, Jarcuska P, Steib C, Reiberger T, Acevedo J, Gatti P, Shawcross DL, Zeuzem S, Zipprich A, Piano S, Berg T, Bruns T, Danielsen KV, Coenraad M, Merli M, Stauber R, Zoller H, Ramos JP, Solé C, Soriano G, de Gottardi A, Gronbaek H, Saliba F, Trautwein C, Kani HT, Francque S, Ryder S, Nahon P, Romero-Gomez M, Van Vlierberghe H, Francoz C, Manns M, Garcia-Lopez E, Tufoni M, Amoros A, Pavesi M, Sanchez C, Praktiknjo M, Curto A, Pitarch C, Putignano A, Moreno E, Bernal W, Aguilar F, Clària J, Ponzo P, Vitalis Z, Zaccherini G, Balogh B, Gerbes A, Vargas V, Alessandria C, Bernardi M, Ginès P, Moreau R, Angeli P, Jalan R, Arroyo V, PREDICT STUDY group of the EASL-CLIF CONSORTIUM.

doi: 10.1016/j.jhep.2020.11.019

Hepatology

Cardiopulmonary hemodynamics and C-reactive protein as prognostic indicators in compensated and decompensated cirrhosis

J Hepatol.

Turco L, Garcia-Tsao G, Magnani I, Bianchini M, Costetti M, Caporali C, Colopi S, Simonini E, De Maria N, Banchelli F, Rossi R, Villa E, Schepis F

doi: 10.1016/j.jhep.2017.12.027.

Hepatology

β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial

Lancet.

Villanueva C, Albillos A, Genescà J, Garcia-Pagan JC, Calleja JL, Aracil C, Bañares R, Morillas RM, Poca M, Peñas B, Augustin S, Abraldes JG, Alvarado E, Torres F, Bosch J

Hepatology

MAIT cells are enriched and highly functional in ascites of patients with decompensated liver cirrhosis

Hepatology.

Niehaus CE, Strunz B, Cornillet M, Falk CS, Schnieders A, Maasoumy B, Hardtke S, Manns MP, Rm Kraft A, Björkström NK, Cornberg M

doi: 10.1002/hep.31153.

HepatitisFurther Publications

Decreasing VWF-levels upon NSBB-therapy indicate a decreased risk of further decompensation, ACLF, and death

Clin Gastroenterol Hepatol

Jachs M, Hartl L, Simbrunner B, Bauer D, Paternostro R, Scheiner B, Schwabl P, Stättermayer AF, Pinter M, Eigenbauer E, Quehenberger P, Trauner M, Reiberger T, Mandorfer M

doi: 10.1016/j.cgh.2021.07.012

Hepatology

HDL-related biomarkers are robust predictors of survival in patients with chronic liver failure

J Hepatol.

Trieb M, Rainer F, Stadlbauer V, Douschan P, Horvath A, Binder L, Trakaki A, Knuplez E, Scharnagl H, Stojakovic T, Heinemann Á, Mandorfer M, Paternostro R, Reiberger T, Pitarch C, Amorós A, Gerbes A, Caraceni P, Alessandria C, Moreau R, Clària J, Marsche G, Stauber RE

doi: 10.1016/j.jhep.2020.01.026.

Related content

Short-term hemodynamic effects of β-blockers influence survival of patients with decompensated cirrhosis

Vitamin E Improves Transplant-free Survival and Hepatic Decompensation among Patients with NASH and Advanced Fibrosis

Targeted lipidomics reveals extensive changes in circulating lipid mediators in patients with acutely decompensated cirrhosis

PREDICT identifies precipitating events associated with the clinical course of acutely decompensated cirrhosis

Cardiopulmonary hemodynamics and C-reactive protein as prognostic indicators in compensated and decompensated cirrhosis

β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial

MAIT cells are enriched and highly functional in ascites of patients with decompensated liver cirrhosis

Decreasing VWF-levels upon NSBB-therapy indicate a decreased risk of further decompensation, ACLF, and death

HDL-related biomarkers are robust predictors of survival in patients with chronic liver failure